Cheng Du Sheng Nuo Biotec Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Chengdu Shengnuo Biotechnology Co., Ltd. (hereinafter referred to as "Shengnuo Biotechnology" or "Company") is a high-tech enterprise with core technologies for peptide synthesis and modification, with advanced and efficient peptide drug process research and development and large-scale production capabilities. The main business of the company is independent research and development, production, and sales of peptide raw materials and preparation products with large market capacity and strong competitiveness both domestically and internationally. At the same time, the company relies on its technological advantages in peptide drug research and development and large-scale production to provide innovative peptide pharmaceutical research services, customized production services for peptide products, and technology transfer services for peptide drug production for domestic and foreign pharmaceutical enterprises. In addition, the company also provides the processing of small molecule chemical drug levosimendan formulations and the production, export and sales of levosimendan raw materials. San Nuo Bio has a full process research and development pipeline and industry chain platform for peptide raw materials and formulations, which can provide pharmaceutical research services for peptide innovative drugs and generic drugs from process route design, to small-scale, pilot, process validation, and quality research. It also provides customized production services for raw materials and formulation products required for drug research and commercial production, covering drug discovery, preclinical research, and other aspects, Complete drug development cycle to clinical trials and market sales. The company, relying on its core technology advantages in peptide synthesis and modification, has gained high visibility and recognition in the field of peptide drug research and production. It has provided pharmaceutical research and customized production services for more than 30 projects for new drug research and development enterprises and research institutions such as Suzhou Paige Biology, Biotech Biology, and Ba Jia Yi. Among them, one peptide innovative drug has been approved for marketing and entered the commercial stage, and one peptide innovative drug has been declared for production, Another 10 innovative peptide drugs have entered the clinical trial stage. The company has selected peptide generic drug varieties with large market capacity and strong market competitiveness both domestically and internationally for research and development. It has mastered the large-scale production technology of 15 varieties of raw materials, of which 9 varieties have obtained production approvals in China, 9 varieties have obtained DMF records in the United States (of which 8 varieties are in an active state), and the extended development of 8 peptide preparation varieties has obtained 12 production approvals in China, covering immunity, digestive tract, antiviral Gynecology and obstetrics, diabetes, cardiovascular and cerebrovascular diseases, rare diseases, orthopedics and other areas where polypeptide drugs play an important role. The company's peptide preparation products for injection are the first domestically produced peptide drugs to be imitated, including enfvectide and carbetocin injection; Imitation raw materials with high synthesis difficulties, such as bivaloudine, liraglutide, thymosin, ateban, and enfviride, have been exported to international markets such as Europe, America, India, and South Korea. End customers include well-known domestic and foreign pharmaceutical companies such as Fresenius, Aurobindo, Mylan, Lupin, Xinlitai, Shanghai Pharmaceutical First Biochemical, and Yangtze River; The industrial research and development of five varieties, including atoxicillin acetate, octreotide acetate, somatostatin acetate, thymosin, and cabetocin, have been included in the "National Major New Drug Development Special Project for the 11th Five Year Plan"; The company has submitted an application for drug registration, and the two formulations of etibant and posaconazole have been included in the "First Batch of Encouraged Imitation Drugs Catalogue" by the National Health Commission. Sano Bio and its subsidiaries have a total of 43 authorized patents, including 32 invention patents, 9 utility model patents, and international PTC2 patents. In addition, the company also possesses a large number of non patented technologies, mainly pharmaceutical production formulas and corresponding production and processing processes. We have been awarded more than ten national and provincial scientific research and technological transformation projects, and have collaborated with West China Hospital of Sichuan University to establish the "Sichuan Peptide Drug Engineering Technology Research Center". We have been awarded the "Sichuan Enterprise Technology Center" by the Sichuan Provincial Economic and Information Technology Commission, playing an important role in the research and industrialization of peptide drugs in China. |
| Headquarter | Chengdu |
| Establish Date | 7/23/2001 |
| Listed Code | 688117.SH |
| Listed Date | 6/3/2021 |
| Chairman | Wen Yongjun. |
| CEO | Wen Yongjun. |
| Website | www.snbiopharm.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
